Related Experiment Video
Updated: Jun 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
High CDC20 levels increase sensitivity of cancer cells to MPS1 inhibitors
Siqi Zheng1, Linoy Raz2, Lin Zhou1
1European Research Institute for the Biology of Ageing, University of Groningen, 1, Antonius Deusinglaan, 9713 AV, Groningen, The Netherlands.
Abstract:
Spindle assembly checkpoint (SAC) inhibitors are a recently developed class of drugs, which perturb chromosome segregation during cell division, induce chromosomal instability (CIN), and eventually lead to cell death. The molecular features that determine cellular sensitivity to these drugs are not fully understood. We recently reported that aneuploid cancer cells are preferentially sensitive to SAC inhibition. Here we report that sensitivity to SAC inhibition by MPS1 inhibitors is largely driven by the expression of CDC20, a main mitotic activator of the anaphase-promoting complex (APC/C), and that the effect of CDC20 is larger than that of the APC/C itself. Mechanistically, we discovered that CDC20 depletion prolongs metaphase duration, diminishes mitotic errors, and reduces sensitivity to SAC inhibition. We found that aneuploid cells express higher basal levels of CDC20, which shortens the duration of metaphase and leads to multiple mitotic errors, resulting in increased long-term sensitivity to the additional CIN induced by SAC inhibition. Our findings propose high CDC20 expression as a molecular feature associated with the sensitivity to SAC inhibition therapy and as a potential aneuploidy-induced cellular vulnerability.
Insights
Spindle assembly checkpoint (SAC) inhibitors are sensitive to high CDC20 expression. This sensitivity is linked to aneuploidy, a cellular vulnerability that shortens metaphase and increases mitotic errors, enhancing drug efficacy.
Area of Science:
- Cell Biology
- Cancer Therapeutics
- Molecular Oncology
Background:
- Spindle assembly checkpoint (SAC) inhibitors are novel drugs that disrupt chromosome segregation, leading to chromosomal instability (CIN) and cell death.
- The precise molecular determinants of cellular sensitivity to SAC inhibitors remain unclear.
- Previous research indicated that aneuploid cancer cells exhibit heightened sensitivity to SAC inhibition.
Purpose of the Study:
- To investigate the molecular drivers of sensitivity to SAC inhibition, particularly by MPS1 inhibitors.
- To elucidate the role of CDC20, a key activator of the anaphase-promoting complex (APC/C), in mediating cellular responses to SAC inhibitors.
- To explore the relationship between aneuploidy, CDC20 expression, and sensitivity to SAC inhibition therapy.
Main Methods:
- Investigated the impact of CDC20 expression levels on cellular sensitivity to SAC inhibitors.
- Utilized MPS1 inhibitors as a model for SAC inhibition.
- Analyzed metaphase duration, mitotic error rates, and CIN induction in response to CDC20 modulation and SAC inhibition.
- Compared CDC20 expression and SAC inhibitor sensitivity in aneuploid versus euploid cancer cells.
Main Results:
- Sensitivity to MPS1 inhibitors is predominantly determined by CDC20 expression, with a greater effect than APC/C itself.
- Depletion of CDC20 prolongs metaphase, reduces mitotic errors, and decreases sensitivity to SAC inhibition.
- Aneuploid cells exhibit higher basal CDC20 levels, leading to shorter metaphase durations and increased susceptibility to SAC inhibitor-induced CIN.
Conclusions:
- High CDC20 expression is a key molecular feature predicting sensitivity to SAC inhibition therapy.
- Aneuploidy-induced elevation of CDC20 creates a cellular vulnerability that enhances the efficacy of SAC inhibitors.
- Findings suggest CDC20 as a potential biomarker for patient stratification in SAC inhibitor-based cancer treatments.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity
Mitogens and the Cell Cycle

